Page last updated: 2024-11-03

propidium and Neuromyelitis Optica

propidium has been researched along with Neuromyelitis Optica in 1 studies

Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.

Neuromyelitis Optica: A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.

Research Excerpts

Excerpt	Relevance	Reference
"Neuromyelitis optica is an inflammatory demyelinating central nervous system disease, usually relapsing, that causes variable degrees of attack-related disability."	1.35	Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. ( Apiwattanakul, M; Fryer, JP; Hinson, SR; Lennon, VA; McKeon, A; Pittock, SJ, 2009)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hinson, SR	1
McKeon, A	1
Fryer, JP	1
Apiwattanakul, M	1
Lennon, VA	1
Pittock, SJ	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica[NCT00904826]			Phase 1/Phase 2	14 participants (Actual)	Interventional	2009-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Expanded Disability Status Scale (EDDS) Score

The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments. (NCT00904826)
Timeframe: baseline, 12 months

Intervention	units on a scale (Mean)
Eculizumab	-0.7

Mean Eculizumab Concentration in Cerebrospinal Fluid (CSF)

(NCT00904826)
Timeframe: 3 months

Intervention	ng/mL (Mean)
Eculizumab	34.7

Number of Subjects With Change in Ambulation by at Least 1 Point

Ambulation was measured by the Hauser Ambulation Index, which ranges from 0 (asymptomatic; fully active) to 9 (restricted to wheelchair; unable to transfer self independently.) (NCT00904826)
Timeframe: 12 months

Intervention	participants (Number)
Eculizumab	3

Number of Subjects With Change in Visual Acuity in at Least One Eye by at Least One Point

Visual acuity was measured using the the Visual Acuity subscale of the Opticospinal Impairment Score (OSIS) for Exacerbations. This subscale ranges from 0 (normal) to 8 (no light perception). (NCT00904826)
Timeframe: 12 months

Intervention	participants (Number)
Eculizumab	5

Number Subjects Experiencing an NMO Attack in 12 Months of Eculizumab Treatment

(NCT00904826)
Timeframe: 12 months

Intervention	participants (Number)
Eculizumab	2

Mean Complement Protein 5 (C5) Concentration in CSF

(NCT00904826)
Timeframe: baseline, 3 months

Intervention	ng/mL (Mean)
	Baseline	3 months
Eculizumab	144	60.8

Mean Serum Concentration of Eculizumab

(NCT00904826)
Timeframe: 6 weeks, 3 months, 6 months, 9 months, 12 months

Intervention	micrograms/mL (Mean)
	6 weeks	3 months	9 months	12 months
Eculizumab	206	187	230	246

Median Number of Neuromyelitis Optica (NMO) Attacks Per Year

(NCT00904826)
Timeframe: baseline, after 12 months of treatment

Intervention	attacks per year (Median)
	Baseline	After 12 months of treatment
Eculizumab	3	0

Percentage Hemolysis

Percentage of hemolysis is a measure of complement activity. Less than 20% lysis is deemed to be complete complement inhibition. (NCT00904826)
Timeframe: baseline, 6 weeks, 3 months, 6 months, 9 months, 12 months

Intervention	percentage of hemolysis (Mean)
	Baseline	6 weeks	3 months	6 months	9 months	12 months
Eculizumab	88.5	0.4	0	0.2	0.4	0.9

Other Studies

1 other study available for propidium and Neuromyelitis Optica

Article	Year
Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Archives of neurology, 2009, Volume: 66, Issue:9 Topics: Adolescent; Adult; Aged; Aquaporin 4; Astrocytes; Biomarkers; Cell Line; Child; Complement Activatio	2009